Evaluation of the Effects of Semen Incubation With ANDROSITOL DGN on Sperm Motility and Mitochondrial Membrane Potential
-
- STATUS
- Recruiting
-
- participants needed
- 45
-
- sponsor
- University of Catania
Summary
Mitochondria is the cellular organelle responsible for the production of the energy necessary to fuel sperm motility. It has been demonstrated that mitochondrial efficiency is correlated to the fertilizing capacity of the spermatozoon and to the production of high quality embryos. Mitochondria efficiency is measured in the laboratory setting by evaluating the mitochondrial membrane potential.
Myo-inositol is the most represented stereoisomer of the family of inositols and is the only one physiologically concentrated within the seminal plasma. It is essential for sperm maturation and motility and its deficiency is also associated to a reduced sperm count. Myo-inositol promotes motility and allows recovering a higher number of sperm cells after swim-up, both in normospermic patients and in patients with altered seminal parameters.
Scientific studies have shown that semen samples treated in vitro with ANDROSITOLDGN, show an improvement in mitochondrial efficiency that results in an increase in spermatozoa progressive motility. Based on the percentage increase in the progressive motility showed by the spermatozoa after incubation with ANDROSITOLDGN (ANDROSITOLTEST), it is possible to subdivide the semen samples into three categories: low, medium, and high responders.
The aim of the study is to evaluate whether the in vitro response of spermatozoa to ANDROSITOLTEST correlates with the in vivo improvement of seminal parameters after oral treatment with antioxidants and myo-inositol.
Description
Mitochondria is the cellular organelle responsible for the production of the energy necessary to fuel sperm motility. It has been demonstrated that mitochondrial efficiency is correlated to the fertilizing capacity of the spermatozoon and to the production of high quality embryos. Mitochondria efficiency is measured in the laboratory setting by evaluating the mitochondrial membrane potential.
Myo-inositol is the most represented stereoisomer of the family of inositols and is the only one physiologically concentrated within the seminal plasma. It is essential for sperm maturation and motility and its deficiency is also associated to a reduced sperm count. Myo-inositol promotes motility and allows recovering a higher number of sperm cells after swim-up, both in normospermic patients and in patients with altered seminal parameters.
Scientific studies have shown that semen samples, both pathological and normal, treated in vitro with ANDROSITOLDGN - a concentrate solution (66X) containing 133 mg/ml of myo-inositol
- show an improvement in mitochondrial efficiency that results in an increase in spermatozoa progressive motility. Based on the percentage increase in the progressive motility showed by the spermatozoa after incubation with ANDROSITOLDGN (ANDROSITOLTEST), it is possible to subdivide the semen samples into three categories: low, medium, and high responders. High responders have worst mitochondrial function and lower fertilizing capacity, and could represent the category of patients most benefiting from supplementary oral therapy with antioxidants and myo-inositol.
The aim of our study is to evaluate whether the in vitro response of spermatozoa to ANDROSITOLTEST correlates with the in vivo improvement of seminal parameters after oral treatment with antioxidants and myo-inositol. To do this, the investigators will enroll at least 13 patients for each category (low, medium, and high responder at ANDROSITOLTEST) and they will re-evaluate conventional seminal parameters, mitochondrial function, and response to ANDROSITOLTEST after three months of oral supplementation with ANDROSITOL (dietary supplement of myo-inositol, vitamin E, L-carnitine, L-arginine, folic acid and selenium). The investigators hypothesize that, following supplementation, high-responder patients will exhibit the best improvement in seminal parameters, in particular in sperm motility. Furthermore, if the mitochondrial function is fully restored, they should respond less to the ANDROSITOLTEST and could be reclassified as low responders.
Details
| Condition | Asthenozoospermia, Mitochondrial Damage |
|---|---|
| Age | 18years - 50years |
| Treatment | ANDROSITOL®TEST |
| Clinical Study Identifier | NCT04291495 |
| Sponsor | University of Catania |
| Last Modified on | 16 February 2024 |
How to participate?
,
Send a message
Enter your contact details to connect with study team
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.